Corcept Therapeutics Incorporated Stock Buy Hold or Sell Recommendation
| CORT Stock | USD 22.48 0.52 2.26% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Corcept Therapeutics Incorporated is 'Cautious Hold'. Macroaxis provides Corcept Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CORT positions. The advice algorithm takes into account all of Corcept Therapeutics' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Corcept Therapeutics' buy or sell advice are summarized below:
Real Value 28.5 | Target Price 34.08 | Hype Value 22.35 | Market Value 22.48 | Naive Value 22.13 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Corcept Therapeutics Incorporated given historical horizon and risk tolerance towards Corcept Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Corcept Therapeutics Incorporated, the advice is generated through an automated system that utilizes algorithms and statistical models.
Corcept |
Execute Corcept Therapeutics Buy or Sell Advice
The Corcept recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Corcept Therapeutics Incorporated. Macroaxis does not own or have any residual interests in Corcept Therapeutics Incorporated or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Corcept Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Corcept Therapeutics Trading Alerts and Improvement Suggestions
| Over 86.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Former Massachusetts Prosecutor and Civil Litigator Glenn Cort Releases New Book Letters to Mikey Messages of Hope and Optimism for Young Adults |
Corcept Therapeutics Returns Distribution Density
The distribution of Corcept Therapeutics' historical returns is an attempt to chart the uncertainty of Corcept Therapeutics' future price movements. The chart of the probability distribution of Corcept Therapeutics daily returns describes the distribution of returns around its average expected value. We use Corcept Therapeutics Incorporated price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Corcept Therapeutics returns is essential to provide solid investment advice for Corcept Therapeutics.
| Mean Return | -0.03 | Value At Risk | -4.07 | Potential Upside | 4.65 | Standard Deviation | 2.76 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Corcept Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Corcept Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Corcept Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Corcept Therapeutics Incorporated backward and forwards among themselves. Corcept Therapeutics' institutional investor refers to the entity that pools money to purchase Corcept Therapeutics' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | D. E. Shaw & Co Lp | 2023-09-30 | 1.5 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.3 M | Arrowstreet Capital Limited Partnership | 2023-12-31 | 1.1 M | Northern Trust Corp | 2023-12-31 | 1.1 M | Goldman Sachs Group Inc | 2023-12-31 | 1.1 M | Charles Schwab Investment Management Inc | 2023-12-31 | 900.4 K | Man Group Plc | 2023-12-31 | 826.1 K | Bank Of New York Mellon Corp | 2023-12-31 | 772.8 K | Norges Bank | 2023-12-31 | 757.5 K | Blackrock Inc | 2023-12-31 | 16.4 M | Vanguard Group Inc | 2023-12-31 | 9.5 M |
Corcept Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Capital Expenditures | 1.1M | 1.2M | 469K | 413K | 139K | 132.1K | |
| End Period Cash Flow | 31.3M | 76.2M | 77.6M | 66.3M | 135.6M | 142.3M | |
| Change In Cash | (10.4M) | 44.9M | 1.4M | (11.3M) | 69.2M | 72.7M | |
| Free Cash Flow | 135.0M | 150.7M | 167.4M | 119.9M | 126.9M | 133.2M | |
| Depreciation | 2.2M | 2.2M | 3.1M | 3.0M | 2.4M | 2.5M | |
| Other Non Cash Items | (1.7M) | 1.5M | 5.1M | 1.4M | (9.1M) | (8.7M) | |
| Net Income | 94.2M | 106.0M | 112.5M | 101.4M | 106.1M | 111.4M | |
| Change To Inventory | (1.0M) | (3.5M) | 3.4M | 1.2M | 1.3M | 1.3M | |
| Change To Netincome | 46.2M | 47.8M | 47.3M | 9.9M | 11.4M | 14.5M | |
| Change Receivables | 10.6M | (2.3M) | (6.3M) | (1.4M) | (1.3M) | (1.3M) | |
| Investments | (116.7M) | (118.0M) | 136.6M | (114.3M) | 56.6M | 59.4M |
Corcept Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Corcept Therapeutics or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Corcept Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Corcept stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.22 | |
β | Beta against NYSE Composite | 2.24 | |
σ | Overall volatility | 2.71 | |
Ir | Information ratio | -0.04 |
Corcept Therapeutics Volatility Alert
Corcept Therapeutics Incorporated exhibits very low volatility with skewness of -0.18 and kurtosis of 0.13. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Corcept Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Corcept Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Corcept Therapeutics Fundamentals Vs Peers
Comparing Corcept Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Corcept Therapeutics' direct or indirect competition across all of the common fundamentals between Corcept Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Corcept Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Corcept Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Corcept Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Corcept Therapeutics to competition |
| Fundamentals | Corcept Therapeutics | Peer Average |
| Return On Equity | 0.21 | -0.31 |
| Return On Asset | 0.11 | -0.14 |
| Profit Margin | 0.22 % | (1.27) % |
| Operating Margin | 0.23 % | (5.51) % |
| Current Valuation | 1.96 B | 16.62 B |
| Shares Outstanding | 103.84 M | 571.82 M |
| Shares Owned By Insiders | 11.41 % | 10.09 % |
| Shares Owned By Institutions | 86.18 % | 39.21 % |
| Number Of Shares Shorted | 21.12 M | 4.71 M |
| Price To Earning | 30.07 X | 28.72 X |
| Price To Book | 4.82 X | 9.51 X |
| Price To Sales | 5.06 X | 11.42 X |
| Revenue | 482.38 M | 9.43 B |
| Gross Profit | 396.47 M | 27.38 B |
| EBITDA | 109.64 M | 3.9 B |
| Net Income | 106.14 M | 570.98 M |
| Cash And Equivalents | 370.09 M | 2.7 B |
| Cash Per Share | 3.45 X | 5.01 X |
| Total Debt | 151 K | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 8.54 X | 2.16 X |
| Book Value Per Share | 4.90 X | 1.93 K |
| Cash Flow From Operations | 127.04 M | 971.22 M |
| Short Ratio | 23.77 X | 4.00 X |
| Earnings Per Share | 0.94 X | 3.12 X |
| Price To Earnings To Growth | 0.61 X | 4.89 X |
| Target Price | 42.73 | |
| Number Of Employees | 352 | 18.84 K |
| Beta | 0.48 | -0.15 |
| Market Capitalization | 2.39 B | 19.03 B |
| Total Asset | 621.52 M | 29.47 B |
| Retained Earnings | 402.53 M | 9.33 B |
| Working Capital | 354.13 M | 1.48 B |
Note: Disposition of 2200 shares by Daniel Swisher of Corcept Therapeutics at 5.86 subject to Rule 16b-3 [view details]
Corcept Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Corcept . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Corcept Therapeutics Buy or Sell Advice
When is the right time to buy or sell Corcept Therapeutics Incorporated? Buying financial instruments such as Corcept Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Accounts Payable | 6.9M | 12.0M | 17.4M | 18.3M | Total Current Liabilities | 6.9M | 81.6M | 104.5M | 109.7M |
Use Investing Ideas to Build Portfolios
In addition to having Corcept Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Utilities Thematic Idea Now
Utilities
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Utilities theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Corcept Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Corcept Stock analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |
Is Corcept Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corcept Therapeutics. If investors know Corcept will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corcept Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.995 | Earnings Share 0.94 | Revenue Per Share 4.658 | Quarterly Revenue Growth 0.314 | Return On Assets 0.1113 |
The market value of Corcept Therapeutics is measured differently than its book value, which is the value of Corcept that is recorded on the company's balance sheet. Investors also form their own opinion of Corcept Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Corcept Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corcept Therapeutics' market value can be influenced by many factors that don't directly affect Corcept Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corcept Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corcept Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corcept Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.